We aim to improve the accuracy and efficiency of anatomic pathology by transforming a manual, analog, and qualitative field into an automated, digitized and quantitative medical science. Our technology will serve medical research and biotechnology industry customers who are creating new diagnostics and therapeutic solutions to improve clinical outcomes and save lives.
Todd Huffman - Founder
Matthew Goodman - Co-Founder
Cody Daniel - Co-Founder
Megan Klimen - Co-Founder
A ‘scientific deli slicer’ that offers pathologists a high-tech look at tumors
STAT - Jul 12, 2016
3Scan raises $14 million for a robotic microscope that could accelerate drug discovery
TechCrunch - Jul 11, 2016
Tissue Analyzer 3Scan Builds Out Machine Learning With $14M Series B
Xconomy - Jul 11, 2016
Arzeda Corporation is inspired by the efficiency, elegance and simplicity of Nature’s synthetic biological processes. Through our foundation in experimental biology, biochemistry and computational design algorithms, we want to expand the horizons of Nature’s chemical and enzyme-engineering capabilities to provide clever solutions for today’s most pressing global needs. By combining the basic biological tools provided by Nature with our advanced understanding of computational design, Arzeda creates innovative cell factories that can transform or supplement current chemical production methods. Our technology enables us to constantly push the boundaries of our understanding and utilization of biological systems to better meet the needs of our industrial customers and partners. Arzeda believes that our ambitious aims are best achieved in a vibrant discovery environment that fosters creativity, integrity and a dedication to scientific rigor and perseverance.
Alexandre Zanghellini - Co-Founder, CEO
Daniela Grabs - Co-Founder, CSO
Eric Althoff - Co-Founder, CBO
David Baker - Co-Founder & Scientific Advisory Board
Biofuels Digest Ranks Arzeda #6 in Annual Hottest Companies in Bioeconomy List
Arzeda - Oct 17, 2017
Arzeda and TeselaGen Partner to Advance Biodesign Technologies for Industrial Biotechnology
Arzeda - Oct 03, 2017
Arzeda Raises $12 Million in Series A Round of Funding Led by OS Fund
Arzeda - Jul 20, 2017
Atomwise is the creator of AtomNet, the first Deep Learning technology for novel small molecule discovery, characterized by its unprecedented speed, accuracy, and diversity.
Research groups that partner with Atomwise gain powerful advantages in the scope, scale, and success rates of their drug discovery programs.
Abraham Heifets - Co-Founder, CEO
Izhar Wallach - Co-Founder, CTO
Alexander Levy - Co-Founder, COO
Monsanto and Atomwise Collaborate to Discover New Crop Protection Options Using Artificial Intelligence Technology
Atomwise - Jun 14, 2017
Atomwise Opens Applications for Historic AI Drug Discovery Awards
Atomwise - Apr 19, 2017
Introducing AtomNet – Drug design with convolutional neural networks
Atomwise - Dec 02, 2015
Offering unprecedented views of the immune system for drug discovery
Christopher Emig - Co-Founder, CEO
Marco Mena - Co-Founder, COO
We are developing next generation technology to store digital information in DNA molecules. Our vision is to fit the information content of entire data centers into the palm of your hand.
We have proven our approach to encoding data in DNA and are in the process of scaling up our platform. The CATALOG technology will make it economically attractive to use DNA as the major medium for long-term archival of data.
Hyunjun Park - Co-Founder, CEO
Nathaniel Roquet - Co-Founder, CSO
Hello from Boston
Catalog - Jul 31, 2017
Join us for Demo Day!
Catalog - Jan 20, 2017
We encoded our first 1kb!
Catalog - Nov 09, 2016
Cleversafe sells an object storage system, which it calls the Dispersed Storage Network or dsNet. Cleversafe was founded in Chicago, Illinois in 2004 by S. Christopher Gladwin and was originally based in IIT's technology incubator.
Chris Gladwin - Founder
Diassess is a medical diagnostic start-up that has developed a test kit that allows any cell phone to perform rapid DNA-based disease detection, in a clinic or at-home, within 30 minutes.
John Waldeisen - Co-Founder, CEO
Elysium’s mission is to solve the biggest challenges in health with science, to help people live healthier, longer. Working directly with the world’s leading scientists and clinicians, Elysium translates advances in science and technology into effective, scientifically sound health products that work.
Eric Marcotulli - Co-Founder, CEO
Dan Alminana - Co-Founder, COO
Leonard Guarente - Co-Founder, Chief Scientist
This Bio-Hacking Anti-Aging Product Has a Unique Cult Following: Doctors
Observer - Jul 27, 2017
An MIT Scientist Claims That This Pill Is the Fountain of Youth
New York - Aug 23, 2016
One Of The World’s Top Aging Researchers Has A Pill To Keep You Feeling Young
Fast Company - Feb 03, 2015
Emerald Cloud Laboratory (ECL) comes from Emerald Therapeutics, our venture-backed biotechnology company based in South San Francisco, California. Emerald was founded by two life-long friends (both Ph.D. scientists) and is staffed by top scientists and engineers from around the world. The ECL was originally developed as an internal product built to streamline research efforts, ensure reproducibility, and provide greater leverage for Emerald's scientists. Now, we are bringing the ECL to the world to provide leaner, more reproducible scientific research to everyone.
DJ Kleinbaum - Co-Founder
Brian Frezza - Co-Founder
Emerald Therapeutics Unveils ECL-1: The First Emerald Cloud Lab Production Facility
Press Release - Mar 25, 2015
Emerald Therapeutics Completes Latest Financing, Brings Total to $13.5MM
Press Release - Jul 01, 2014
Emulate Inc.’s Organs-on-Chips technology places living human cells in micro-engineered environments – to recreate human biology. Emulate's integrated system provides a window into the inner-workings of the human body, and is designed to predict human response with greater precision and detail than today’s cell culture or animal-based testing experimental methods.
Donald Ingber - Founder, Scientific Founder
James Coon - Co-Founder, CEO
Daniel Levner - Co-Founder, CTO
We are developing innovative tools for allergists to improve patient outcomes
Moufeed Kaddoura - Co-Founder, CEO
Eric Blondeel - Co-Founder, CTO
Allergy patch creators ExVivo want you to be able to do at-home testing
CBC - Apr 28, 2016
Ginkgo Bioworks is engineering from nature. Its founders, who hail from MIT and include renowned computer scientist Tom Knight, are redesigning industrial engineering for a new generation, creating a revolution powered by biology.
Jason Kelly - Founder
Reshma Shetty - Founder
Barry Canton - Founder
Austin Che - Founder
Tom Knight - Founder
This Startup Is Engineering Crops That Can Fertilize Themselves
Fast Company - Oct 04, 2017
Bayer joins in $100 million investment bet on ag-biotech startup
Reuters - Sep 14, 2017
Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer
Forbes - Sep 14, 2017
Feeding the world is a vexing problem. Many countries struggle to feed their people, yet one third of Americans are obese, costing the U.S. economy nearly $1 trillion a year. We have a rapidly growing global population, yet our planet is running out of resources. We have less land than ever before, limited water and a fragile ecosystem. We need to find a way to produce healthy food at low cost, even in times of drought or extreme weather.
We need a solution that cuts to the core of the problem.
Hampton Creek is doing just that and rewriting the OS of food. Josh Tetrick, founder and CEO of Hampton Creek, the maker of Just Mayo, Just Cookies and Just Cookie Dough (and many more products to come), is challenging the world’s assumptions about where our food comes from, how it’s made and what healthy food tastes like. His approach is environmentally conscious and foodie friendly.
Josh Tetrick - Co-Founder
Josh Balk - Co-Founder
The Atlantic - Nov 01, 2017
Welcome to the era of health intelligence. Human Longevity, Inc. (HLI) is revolutionizing human health by generating more data and deeper understanding into what can keep you living healthier longer. HLI’s scientists have created the world’s largest database of sequenced genomes and phenotypic (physical traits) data, to uncover unprecedented insights capable of transforming healthcare from reactive to proactive.
Craig Venter - Co-Founder
Robert Hariri - Co-Founder
Peter Diamandis - Co-Founder
STATEMENT FROM HUMAN LONGEVITY INC. ON PNAS PAPER
Press Release - Sep 05, 2017
HUMAN LONGEVITY, INC. RESEARCHERS DEVELOP NEW ALGORITHM TO RAPIDLY AND ACCURATELY PREDICT HLA TYPES
Press Release - Jul 03, 2017
HUMAN LONGEVITY, INC. ANNOUNCES AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY
Press Release - Jun 15, 2017
Founded in 2010, Lygos is providing biotechnology solutions for today’s renewable chemical challenges. We engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production
Eric Steen - Founder, CEO
Jeffrey Dietrich - Founder, CTO
Jay D. Keasling - Founder
Leonard Katz - Founder
Lygos is Awarded National Science Foundation Grant for Research Experience for Undergraduates (REU)
Press Release - Sep 15, 2017
Lygos Appoints Industry Expert Johan van Walsem as COO
Press Release - Jul 25, 2017
Clean Tech Rises Again, Retooling Nature for Industrial Use
New York Times - Nov 27, 2016
There are places in the world, including the majority of Africa and Asia, which completely lack usable roads. A billion people in the world have no access to all-season roads. Alright, so let’s build more roads, right? The solution is not that simple. In order to build African road infrastructure equivalent to America’s, it would take 23 years and cost $4 trillion. In the meantime, millions of people would continue to die each year because they lack access to basic resources such as food and medicine.
Andreas Raptopoulos - Founder, CEO
Delivery Drones Are Using Vans as Roving Parcel Hubs in Switzerland
Technology Review - Sep 29, 2017
Switzerland's New Medical Drones
Time - Sep 28, 2017
Mercedes-Benz kicks off drone delivery pilot in Zurich
TechCrunch - Sep 28, 2017
A simple blood test to detect disease at the molecular level. We believe everyone should have access to accurate, affordable and minimally invasive diagnostic tools.
Alejandro Tocigl - Founder, CEO
Jorge Soto - Founder, CTO
Foteini Christodoulou - Founder, CSO
AstraZeneca teams with Emulate to use organ-on-a-chip tech for R&D
FierceBiotech - May 16, 2018
Emulate, Inc. Awarded Grant to Fund use of Human Emulation System aboard the International Space Station
Press Release - Jun 20, 2017
New Data from Emulate’s Asthma-on-Chip Presented at American Thoracic Society Annual Meeting
Press Release - May 23, 2017
FDA Signs Collaborative Agreement with Emulate, Inc. to Use Organs-on-Chips Technology
Press Release - Apr 11, 2017
Our mission is to enable temperature-sensitive vaccines and therapeutics to be stable without refrigeration so they can be easily transported to anywhere in the world
Nanxi Liu - Founder
6 Innovations That Could Change Our Future
SciencePost.fr - Jun 25, 2015
This Sci-Fi Material Will Keep Vaccines Nice And Chilly (Which Means They Still Work)
Fast Company - Dec 12, 2013
Nanoly Bioscience to develop CU-Boulder vaccine stabilization technology
CU Boulder Today - Sep 11, 2013
NuMat Technologies solves the world's toughest problems at the atomic level. We do this by designing material-enabled hardware systems that uniquely store, harvest and produce high-value resources the world needs
Benjamin Hernandez - Co-Founder, CEO
Omar Farha - Co-Founder, CSO
Christopher Wilmer - Co-Founder
Where others see billions of microbes intertwined within the crop microbiome, we see limitless possibilities to unlock powerful new solutions. At Pivot Bio, we’re pioneering a groundbreaking approach to crop nutrition — forging a path to better yields, healthier soils and a brighter future for our world
Karsten Temme - Co-Founder, CEO
Alvin Tamsir - Co-Founder, CSO
Chris Voigt - Co-Founder
Microbiome Startup Pivot Bio in $16m Series A
AG Funder News - Mar 24, 2016
Plethora is a mission-driven startup that builds software, hardware, and operates a factory to empower everyone on Earth to invent anything
Nick Pinkston - Founder
Jeremy Herrman - Founder
An Introduction to Workholding
Plethora - Oct 31, 2017
Hacking the Digital Hardware Prototype Through Simulation Software
Plethora - Oct 19, 2017
Maker Spotlight | MVS brings innovation to the BMX community
Plethora - Oct 11, 2017
We specialize in the rapid development of biosensors for the detection of small molecules
Giles Ochs - Founder
Cameron Strachan - Founder
Ginkgo Bioworks and Prospect Bio to Collaborate on Tools to Accelerate Biological Engineering
Press Release - Oct 19, 2016
GINKGO PARTNERSHIP COVERED IN SYNBIOBETA
Synbiobeta - Oct 19, 2016
Synthego is a leading provider of genome engineering solutions. Our flagship product, CRISPRevolution, is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Synthego’s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.
Alex Pesch - Founder
Michael Dabrowski - Founder
Paul Dabrowski - Founder
Translating scientific breakthroughs into breakthrough products
Synthetic Genomics Inc. (SGI) is a global leader in the fields of synthetic biology and synthetic genomics utilizing our foundational intellectual property in these rapidly evolving disciplines to design and build biological systems to solve global sustainability challenges.
SGI provides solutions in genomics research, bioproduction, and applied products. Our research segment is focused on genomics solutions for academic and commercial R&D organizations. The commercial products and services include instrumentation, reagents, DNA synthesis services, and bioinformatics services and software.
David Kiernan - Co-Founder
Juan Enriquez - Co-Founder
Hamilton Smith - Co-Founder
Synthetic Genomics and Ceva Enter Agreement to Develop, Commercialize Next-Generation Vaccines for Animal Health
Press Release - Oct 31, 2017
Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics
Synthetic Genomics Partners with Duke Human Vaccine Institute on DARPA Pandemic Prevention Platform Program
Press Release - Oct 26, 2017
We're creating a world where electronics development can move as fast as software development.
Electronics development today is slow and tedious, because low-volume orders are forced through a manual, high-volume process. We’ve built a software-driven process optimized for low volume, allowing you to cut down development times and enjoy a seamless ordering experience.
Shashank Samala - Co-Founder
Jesse Koenig - Co-Founder
Jeff McAlvay - Co-Founder
Katherine Scott - Co-Founder
twoXAR is an artificial intelligence-driven drug discovery company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships.
Andrew A. Radin - CEO & Co-Founder
Andrew M. Radin - Chief Marketing Officer & Co-Founder
Moving drug discovery into the fast lane: OS Fund invests in twoXAR’s AI-driven approach
Medium - Mar 19, 2018
twoXAR teams up with SoftBank Ventures, Andreessen Horowitz, and OS Fund to identify new treatments for patients
TwoXar raises $10 million from SoftBank, Andreessen Horowitz, and OS Fund to grow its AI drug discovery platform
VentureBeat - Mar 19, 2018
uBiome is the leading microbial genomics company.
We are pioneering a new era of microbiome-based precision medicine. We allow doctors, patients, and citizen scientists to learn about the human microbiome with unprecedented accuracy and speed.
Zachary Apte - Founder
Jessica Richman - Founder
uBiome Publishes Peer-Reviewed Scientific Paper in PLOS ONE on First Version of Technology for Gut Health Screening Test
Press Release - Nov 02, 2017
uBiome and Jackson Laboratory for Genomic Medicine to Study Pathogen Transmission in Geriatric Communities
uBiome Grant Will Enable UCSF Scientist to Explore ‘Spit Test’ to Predict Blood Infections in Young Bone Marrow Transplant Patients
We use machine learning and human genomic data to accelerate the discovery of new treatments for patients with neurodegenerative diseases.
Alice Zhang - Co-Founder, CEO
Jason Chen - Co-Founder, Advisor
Verge Genomics Announces a Multi-Institution Collaboration with Columbia University, MGH, USC, and University of Michigan to Advance ALS Research
Verge Genomics Appoints Tony Altar, Ph.D., as Chief Scientific Officer
Press Release - May 10, 2017
30 Under 30 In Science 2017: Discovering New Things About Our World And New Ways To Save It
Forbes - Jan 03, 2017
Vicarious is developing artificial general intelligence for robots. By combining insights from generative probabilistic models and systems neuroscience, our architecture trains faster, adapts more readily, and generalizes more broadly than AI approaches commonly used today.
D. Scott Phoenix - Founder
Dileep George - Founder
Greg Gretsch - Founder
Beyond Deep Learning: Computers That Improvise
Forbes - Aug 01, 2017
Khosla Bets on AI for Robots That Handle ‘Uncertainty’
Wall Street Journal - Jul 25, 2017
Khosla Ventures leads $50 million investment in Vicarious’ AI tech
VentureBeat - Jul 25, 2017
Viv is an artificial intelligence platform that enables developers to distribute their products through an intelligent, conversational interface. It’s the simplest way for the world to interact with devices, services and things everywhere. Viv is taught by the world, knows more than it is taught, and learns every day.
Adam Cheyer - Founder
Chris Brigham - Founder
Dag Kittlaus - Founder
The future of robots and artificial intelligence
CBS - Jun 14, 2017
Viv Will Replace Your Smartphone With Your Fridge and Then Take Over the World
Esquire - Apr 28, 2015
SIRI'S INVENTORS ARE BUILDING A RADICAL NEW AI THAT DOES ANYTHING YOU ASK
Wired - Aug 12, 2014
LINKEDIN | TWITTER | MEDIUM | FACEBOOK
ABOUT | NEWS | COMPANIES | MANIFESTO | CONTACT
© 2019 OS Fund